



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 22 May 2017 (#18)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa de Vries [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)) to inform of your intent to apply.

## **Timelines:**

Confirm your intent to apply **as soon as possible, but not later than 30 days** before the submission date.

All final application documents **MUST reach the RGMO seven (7) workdays** before NIH application due date.

The application will be submitted **four (4) workdays** before the application due date.

### **1. Silencing of HIV-1 Proviruses**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AI-17-013\)](#)

**Type:** R61/R33

**Application Due Date:** December 6, 2017. Apply by 5:00 PM local time of applicant organization.

**This Funding Opportunity Announcement (FOA)** encourages exploratory and developmental bi-phasic research applications to support the identification and optimization of small molecules or RNAs that interact with host epigenetic machinery to mediate long-term or permanent epigenetic silencing of HIV-1 proviruses

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$4.7M to fund 6-9 awards in FY18. Application budgets are limited to \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 3 years for the R61 phase and up to 2 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible.

### **2. Addressing Suicide Research Gaps: Aggregating and Mining Existing Data Sets for Secondary**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-MH-18-400\)](#)

**Type:** R01

**Application Due Date:** November 2, 2017. Apply by 5:00 PM local time of applicant organization.

**This Funding Opportunity Announcement (FOA)** seeks to leverage data from existing basic, clinical, and intervention research on suicide risk and behaviors as well as social media and healthcare records data, by encouraging the integration of existing data sets for novel secondary analyses aimed at identifying potential biological, experiential, and other predictors and moderators of suicide risk. The use of dimensional variables and inclusion of multiple levels of analyses is particularly encouraged. A secondary goal of this FOA is to support innovative projects that will generate foundational work for research studies on suicide-related behaviors that inform a Research Domain Criteria (RDoC) approach in this area. Projects supported by this FOA will help address gaps identified in the [2014 Prioritized Research Agenda for Suicide Prevention](#)

**Budget:** NIMH intends to commit \$2 million in FY 2018 to fund 3-5 meritorious applications. NCCIH intends to commit up to \$500,000 to support 1 meritorious application of clear relevance to its mission. NIAAA intends to commit up to \$50,000 total costs, to cofund 1 award. NIDA intends to commit up to \$500,000 to support 1 meritorious application. OBSSR intends to commit up to \$250,000 to support meritorious applications. Application budgets are limited to \$300,000 in direct costs (not including consortium F&A) in any project year, and need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

### **3. HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-17-291\)](#)  
[\(PA-17-292\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**This Funding Opportunity Announcement (FOA)** supports studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between minority variants and treatment outcomes and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

**Budget:** R01: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

**D71 - International Research Training Planning Grant:** To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

**D43 - International Research Training Grants:** To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

**R25 – NIH Education Projects:** used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

**R34 - Clinical Trial Planning Grant Program:** To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

**R35 - Outstanding Investigator Award:** To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U24 – Resource-Related Research Projects – Cooperative Agreements:** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**U19 - Research Program-Cooperative Agreements:** supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.